IN THE SPECIFICATION

Please insert the following paragraph at page 1 after the title:

This application is a national stage of PCT/FR99/02938, filed November 26, 1999, which claims the benefit of FRANCE 98/15074, filed November 30, 1998.

Please insert the following paragraphs before Example 1 at page 13 after line 15:

BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 shows preparation of doxorubicin-Succ-peptides.

Fig. 2 shows preparation of doxorubicin-SMP-3MP-peptides.

Fig. 3 shows penetration of doxorubicin, Compound No. 1 and Compound No. 2 into the brain.

Fig. 4 shows penetration of doxorubicin, Compound No. 1 and Compound No. 2 into brain structures.

Fig. 5 shows penetration of doxorubicin, Compound No. 1 and Compound No. 2 into brain structures after rinsing.

Fig. 6 shows product distribution of doxorubicin, Compound No. 1 and Compound No. 2 after capillary depletion.

Fig. 7 shows penetration of dalargine and dal-SynB1 into the brain.

Fig. 8 shows analgesic activity of vectorized dalargine.

Fig. 9 shows penetration of doxorubicin and dox-SynB3 into the brain.

Fig. 10 shows product distribution of doxorubicin and dox-SynB3 into brain structures.

Fig. 11 shows product distribution of doxorubicin and dox-SynB3 into the brain after capillary depletion.

Fig. 12 shows synthesis of N-benzyl-penicillin-SynBl.

Fig. 13 shows penetration of penicillin (PNC) and PNC-SynB1 into the brain.

Fig. 14 shows product distribution of penicillin (PNC) and PNC-SynB1 into the brain.

Fig. 15 shows product distribution of penicillin (PNC) and PNC-SynB1 into the brain after capillary depletion.